Chris Mansi, MD is CEO and Co-Founder of Viz.ai, the leader in AI-powered disease detection and care coordination.  Viz.ai’s mission is to improve access to life saving treatments for more than 230 million people that it covers.  Today, the Viz.ai One Platform has more than 50 FDA-cleared AI algorithms, is adopted in more than 1,800 hospitals, and collaborates with 11 of the leading, global pharmaceutical and medical device companies.

Dr. Mansi co-founded Viz.ai out of Stanford in 2016 and under his leadership, Viz.ai has achieved major AI industry milestones, including two de novo approvals by the FDA for AI computer aided triage in 2018 and cardiovascular machine learning-based notification software in 2023.  Viz.ai was also the first AI company to be granted CMS reimbursement via the New Technology Add-on Payment (NTAP) for AI in 2020.   In 2024, Viz.ai was named one of the 50 world’s most innovative companies by Fast Company Magazine, and Chris was recognized as in Time Magazine’s 100 Most Influential People in AI in 2024.